Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers.
Geller MA, Cooley S, Argenta PA, Downs LS, Carson LF, Judson PL, Ghebre R, Weigel B, Panoskaltsis-Mortari A, Curtsinger J, Miller JS. Geller MA, et al. Among authors: miller js. Cancer Immunol Immunother. 2010 Dec;59(12):1877-1884. doi: 10.1007/s00262-010-0914-1. Epub 2010 Sep 5. Cancer Immunol Immunother. 2010. PMID: 20820775 Free PMC article. Clinical Trial.
A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.
Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, Jonson AL, Panoskaltsis-Mortari A, Curtsinger J, McKenna D, Dusenbery K, Bliss R, Downs LS, Miller JS. Geller MA, et al. Among authors: miller js. Cytotherapy. 2011 Jan;13(1):98-107. doi: 10.3109/14653249.2010.515582. Epub 2010 Sep 20. Cytotherapy. 2011. PMID: 20849361 Free PMC article. Clinical Trial.
Use of allogeneic NK cells for cancer immunotherapy.
Geller MA, Miller JS. Geller MA, et al. Among authors: miller js. Immunotherapy. 2011 Dec;3(12):1445-59. doi: 10.2217/imt.11.131. Immunotherapy. 2011. PMID: 22091681 Free PMC article. Review.
Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9.
Gleason MK, Lenvik TR, McCullar V, Felices M, O'Brien MS, Cooley SA, Verneris MR, Cichocki F, Holman CJ, Panoskaltsis-Mortari A, Niki T, Hirashima M, Blazar BR, Miller JS. Gleason MK, et al. Among authors: miller js. Blood. 2012 Mar 29;119(13):3064-72. doi: 10.1182/blood-2011-06-360321. Epub 2012 Feb 8. Blood. 2012. PMID: 22323453 Free PMC article.
Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.
Gleason MK, Verneris MR, Todhunter DA, Zhang B, McCullar V, Zhou SX, Panoskaltsis-Mortari A, Weiner LM, Vallera DA, Miller JS. Gleason MK, et al. Among authors: miller js. Mol Cancer Ther. 2012 Dec;11(12):2674-84. doi: 10.1158/1535-7163.MCT-12-0692. Epub 2012 Oct 17. Mol Cancer Ther. 2012. PMID: 23075808 Free PMC article.
Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells.
Vallera DA, Zhang B, Gleason MK, Oh S, Weiner LM, Kaufman DS, McCullar V, Miller JS, Verneris MR. Vallera DA, et al. Among authors: miller js. Cancer Biother Radiopharm. 2013 May;28(4):274-82. doi: 10.1089/cbr.2012.1329. Epub 2013 Apr 23. Cancer Biother Radiopharm. 2013. PMID: 23611188 Free PMC article.
Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.
Wiernik A, Foley B, Zhang B, Verneris MR, Warlick E, Gleason MK, Ross JA, Luo X, Weisdorf DJ, Walcheck B, Vallera DA, Miller JS. Wiernik A, et al. Among authors: miller js. Clin Cancer Res. 2013 Jul 15;19(14):3844-55. doi: 10.1158/1078-0432.CCR-13-0505. Epub 2013 May 20. Clin Cancer Res. 2013. PMID: 23690482 Free PMC article.
1,124 results